Resverlogix Corp.
RFS.F
0.06 EUR
1 day: 0.0% (0.00 EUR)
The alert is saved directly without jumping back to the homepage.
Price alerts for RFS.F
Please log in to view and save price alerts.
Finanzen
Company info
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Aktuelle News
-
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
Vorschau anzeigen
Calgary, Alberta--(Newsfile Corp. - June 25, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected Five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:Votes ForVotes WithheldPercent ForPercent WithheldDonald J....
-
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Vorschau anzeigen
Calgary, Alberta--(Newsfile Corp. - May 19, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (the "Transaction") with an arm's length subscriber (the "Subscriber"). Under the terms of the Transaction, the Subscriber subscribed for 26,864,133 common shares at CAD$0.103 per share, equal to the applicable 5-day volume-weighted average price, for aggregate proceeds of CAD$2,760,057...
-
Resverlogix Announces One-Year Extension of Debenture
Vorschau anzeigen
Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026."We appreciate...
-
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Vorschau anzeigen
Calgary, Alberta--(Newsfile Corp. - April 16, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces the revocation, effective April 15, 2026, of a management cease trade order ("MCTO") issued by the Alberta Securities Commission (the "ASC") on April 1, 2026 at the request of the Company.The Company filed its audited financial statements, management's discussion & analysis, certifications of annual filings, and annual information form for the year ended December 31, 2025
-
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
Vorschau anzeigen
The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as Olpasiran (AMG 890) (Amgen/Arrowhead Pharmaceuticals), Obicetrapib (TA-8995) (Newamsterdam Pharma/Menarini), Apabetalone (RVX000222) (Resverlogix), Pelacarsen (TQJ230) (Ionis Pharmaceuticals/Novartis), and others, and the increasing prevalence of ASCVD.New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) --